Früh, Martin

Up a level
Export as [feed] RSS
Group by: Date | Item Type | Refereed | No Grouping
Jump to: 2023 | 2022 | 2021 | 2020 | 2019 | 2017


Nuñez, Nicolas Gonzalo; Berner, Fiamma; Friebel, Ekaterina; Unger, Susanne; Wyss, Nina; Gomez, Julia Martinez; Purde, Mette-Triin; Niederer, Rebekka; Porsch, Maximilian; Lichtensteiger, Christa; Kramer, Rafaela; Erdmann, Michael; Schmitt, Christina; Heinzerling, Lucie; Abdou, Marie-Therese; Karbach, Julia; Schadendorf, Dirk; Zimmer, Lisa; Ugurel, Selma; Klümper, Niklas; ... (2023). Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. Med (N Y), 4(2), 113-129.e7. Cell Press 10.1016/j.medj.2022.12.007


Furrer, Katarzyna; Weder, Walter; Eboulet, Eric Innocents; Betticher, Daniel; Pless, Miklos; Stupp, Roger; Krueger, Thorsten; Perentes, Jean Yannis; Schmid, Ralph A; Lardinois, Didier; Furrer, Markus; Früh, Martin; Peters, Solange; Curioni-Fontecedro, Alessandra; Stahel, Rolf A; Rothschild, Sacha I; Hayoz, Stefanie; Opitz, Isabelle (2022). Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment. The journal of thoracic and cardiovascular surgery, 164(6), 1587-1602.e5. Elsevier 10.1016/j.jtcvs.2022.03.034

Sun, Suna; Qi, Weihong; Rehrauer, Hubert; Ronner, Manuel; Hariharan, Ananya; Wipplinger, Martin; Meiller, Clément; Stahel, Rolf; Früh, Martin; Cerciello, Ferdinando; Fonteneau, Jean-François; Jean, Didier; Felley-Bosco, Emanuela (2022). Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma. JTO clinical and research reports, 3(12), p. 100430. 10.1016/j.jtocrr.2022.100430

Addeo, Alfredo; Rothschild, Sacha I; Holer, Lisa; Schneider, Martina; Waibel, Christine; Haefliger, Simon; Mark, Michael; Fernandez, Eugenio; Mach, Nicolas; Mauti, Laetitia; Jermann, Philip M; Alborelli, Ilaria; Calgua, Byron; Savic-Prince, Spasenija; Joerger, Markus; Früh, Martin (2022). Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. Lung cancer, 172, pp. 154-159. Elsevier 10.1016/j.lungcan.2022.08.016

Berner, Fiamma; Bomze, David; Lichtensteiger, Christa; Walter, Vincent; Niederer, Rebekka; Hasan Ali, Omar; Wyss, Nina; Bauer, Jens; Freudenmann, Lena Katharina; Marcu, Ana; Wolfschmitt, Eva-Maria; Haen, Sebastian; Gross, Thorben; Abdou, Marie-Therese; Diem, Stefan; Knöpfli, Stella; Sinnberg, Tobias; Hofmeister, Kathrin; Cheng, Hung-Wei; Toma, Marieta; ... (2022). Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. Science immunology, 7(75), eabn9644. American Association for the Advancement of Science 10.1126/sciimmunol.abn9644

Mark, M; Rusakiewicz, S; Früh, M; Hayoz, S; Grosso, F; Pless, M; Zucali, P; Ceresoli, G L; Maconi, A; Schneider, M; Froesch, P; Tarussio, D; Benedetti, F; Dagher, J; Kandalaft, L; von Moos, R; Tissot-Renaud, S; Schmid, S; Metaxas, Y (2022). Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study. ESMO open, 7(3), p. 100446. BMJ 10.1016/j.esmoop.2022.100446

König, D; Schär, S; Vuong, D; Guckenberger, M; Furrer, K; Opitz, I; Weder, W; Rothschild, S I; Ochsenbein, A; Zippelius, A; Addeo, A; Mark, M; Eboulet, E I; Hayoz, S; Thierstein, S; Betticher, D C; Ris, H-B; Stupp, R; Curioni-Fontecedro, A; Peters, S; ... (2022). Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]. ESMO open, 7(3), p. 100494. Elsevier 10.1016/j.esmoop.2022.100494

Dafni, U; Soo, R A; Peters, S; Tsourti, Z; Zygoura, P; Vervita, K; Han, J-Y; De Castro, J; Coate, L; Früh, M; Hashemi, S M S; Nadal, E; Carcereny, E; Sala, M A; Bernabé, R; Provencio, M; Cuffe, S; Roschitzki-Voser, H; Ruepp, B; Rosell, R; ... (2022). Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis. ESMO open, 7(3), p. 100507. Elsevier 10.1016/j.esmoop.2022.100507

Purde, Mette‑Triin; Niederer, Rebekka; Wagner, ikolaus B.; Diem, Stefan; Berner, Fiamma; Hasan Ali, Omar; Hillmann, Dorothea; Bergamin, Irina; Joerger, Markus; Risch, Martin; Niederhauser, Christoph; Lenz, Tobias L.; Früh, Martin; Risch, Lorenz; Semela, David; Flatz, Lukas (2022). Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. Journal of cancer research and clinical oncology, 148(3), pp. 647-656. Springer 10.1007/s00432-021-03870-6

Koster, Kira-Lee; Appenzeller, Christina; Lauber, Arno; Früh, Martin; Schmid, Sabine (2022). Sotorasib Shows Intracranial Activity in Patients with KRAS G12C-Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases. Case reports in oncology, 15(2), pp. 720-725. Karger 10.1159/000525341

Neff, Dominik; Padberg Sgier, Barbara-Christina; Dietze, Hannah; Müller, Joachim; Früh, Martin (2022). Unusually Aggressive Presentation of Malignant Peritoneal Mesothelioma: Two Case Reports. Case reports in oncology, 15(3), pp. 1001-1008. Karger 10.1159/000526974


Rothschild, Sacha I; Zippelius, Alfred; Eboulet, Eric I; Savic Prince, Spasenija; Betticher, Daniel; Bettini, Adrienne; Früh, Martin; Joerger, Markus; Lardinois, Didier; Gelpke, Hans; Mauti, Laetitia A; Britschgi, Christian; Weder, Walter; Peters, Solange; Mark, Michael; Cathomas, Richard; Ochsenbein, Adrian F; Janthur, Wolf-Dieter; Waibel, Christine; Mach, Nicolas; ... (2021). SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. Journal of clinical oncology, 39(26), pp. 2872-2880. American Society of Clinical Oncology 10.1200/JCO.21.00276


Putora, Paul Martin; Fischer, G F; Früh, Martin; Califano, R; Faivre-Finn, C; Van Houtte, P; McDonald, F; Nestle, U; Dziadziuszko, R; Le Pechoux, C; Ramella, S; Belderbos, J; Slotman, B J; Troost, E G C; Peeters, S; Widder, J; Pöttgen, C; Reck, M; Blackhall, F; Cappuzzo, F; ... (2020). Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 149, pp. 84-88. Elsevier Scientific Publ. Ireland 10.1016/j.radonc.2020.04.015

Früh, M.; Panje, C.M.; Reck, M; Blackhall, F; Califano, R; Cappuzzo, F; Besse, B; Novello, S; Garrido, P; Felip, E; O'Brien, M; Paz Ares, L; de Marinis, F; Westeel, V; De Ruysscher, D; Putora, P.M. (2020). Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts. Lung cancer, 146, pp. 6-11. Elsevier 10.1016/j.lungcan.2020.03.024


Früh, Martin; Betticher, Daniel C; Stupp, Roger; Xyrafas, Alexandros; Peters, Solange; Ris, Hans Beat; Mirimanoff, Rene Olivier; Ochsenbein, Adrian F.; Schmid, Ralph; Matzinger, Oscar; Stahel, Rolf A; Weder, Walter; Guckenberger, Matthias; Rothschild, Sacha I; Lardinois, Didier; Mach, Nicholas; Mark, Michael; Gautschi, Oliver; Thierstein, Sandra; Biaggi Rudolf, Christine; ... (2019). Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). Journal of thoracic oncology, 14(1), pp. 115-123. Elsevier 10.1016/j.jtho.2018.09.011


Peters, Solange; Gettinger, Scott; Johnson, Melissa L; Jänne, Pasi A; Garassino, Marina C; Christoph, Daniel; Toh, Chee Keong; Rizvi, Naiyer A; Chaft, Jamie E; Carcereny Costa, Enric; Patel, Jyoti D; Chow, Laura Q M; Koczywas, Marianna; Ho, Cheryl; Früh, Martin; van den Heuvel, Michel; Rothenstein, Jeffrey; Reck, Martin; Paz-Ares, Luis; Shepherd, Frances A; ... (2017). Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). Journal of clinical oncology, 35(24), pp. 2781-2789. American Society of Clinical Oncology 10.1200/JCO.2016.71.9476

Delaunay, Myriam; Cadranel, Jacques; Lusque, Amélie; Meyer, Nicolas; Gounant, Valérie; Moro-Sibilot, Denis; Michot, Jean-Marie; Raimbourg, Judith; Girard, Nicolas; Guisier, Florian; Planchard, David; Metivier, Anne-Cécile; Tomasini, Pascale; Dansin, Eric; Pérol, Maurice; Campana, Marion; Gautschi, Oliver; Früh, Martin; Fumet, Jean-David; Audigier-Valette, Clarisse; ... (2017). Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. European respiratory journal, 50(2) European Respiratory Society 10.1183/13993003.00050-2017

Baty, Florent; Joerger, Markus; Früh, Martin; Klingbiel, Dirk; Zappa, Francesco; Brutsche, Martin (2017). 24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling. Journal of translational medicine, 15(1), p. 66. BioMed Central 10.1186/s12967-017-1174-z

Provide Feedback